Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

10.0%

2 terminated out of 20 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

20%

4 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results60% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (4)
P 1 (1)
P 2 (3)
P 3 (1)
P 4 (3)

Trial Status

Recruiting10
Completed3
Not Yet Recruiting3
Terminated2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07553182Phase 3RecruitingPrimary

OLE Study With Filgotinib in JIA

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07138157Not ApplicableCompleted

Comparison Of The Effects Of Two Different Exercise Training Based On Internal And External Focus In Children and Adolescents With Rheumatic Diseases

NCT06623240Phase 2WithdrawnPrimary

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

NCT07211932Not Yet RecruitingPrimary

Tofacitinib in Juvenile Idiopathic Arthritis

NCT05710640Phase 2TerminatedPrimary

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT07234747Not ApplicableRecruitingPrimary

Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis

NCT07185750RecruitingPrimary

Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients

NCT06591949Not ApplicableCompleted

Cognitive Exercise Therapy Approach (BETY) in JIA

NCT05534347RecruitingPrimary

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT03725007Phase 1Active Not RecruitingPrimary

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

NCT07065747Recruiting

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT03245801RecruitingPrimary

CAPRI National Juvenile Idiopathic Arthritis Registry

NCT06806774RecruitingPrimary

Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic Arthritis

NCT06874608Not ApplicableRecruitingPrimary

Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis

NCT06862843RecruitingPrimary

Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-mediated Inflammatory Pathology. Observational Multicenter Study.

NCT01544114Phase 4CompletedPrimary

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

NCT06705673Not Yet RecruitingPrimary

Gait Profile and Variables in Pediatric Rheumatic Disease Using a Smart Insole System

NCT06618937Phase 4Not Yet RecruitingPrimary

Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission

Showing all 20 trials

Research Network

Activity Timeline